Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study

BACKGROUND: Siponimod is a sphingosine 1-phosphate receptor modulator approved for active secondary progressive multiple sclerosis (aSPMS) in most countries; however, phase 3 EXPAND study data are from an SPMS population with/without disease activity. A need exists to characterize efficacy/safety of...

Descripción completa

Detalles Bibliográficos
Autores principales: Gold, Ralf, Piani-Meier, Daniela, Kappos, Ludwig, Bar-Or, Amit, Vermersch, Patrick, Giovannoni, Gavin, Fox, Robert J., Arnold, Douglas L., Benedict, Ralph H. B., Penner, Iris-Katharina, Rouyrre, Nicolas, Kilaru, Ajay, Karlsson, Göril, Ritter, Shannon, Dahlke, Frank, Hach, Thomas, Cree, Bruce A. C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9363350/
https://www.ncbi.nlm.nih.gov/pubmed/35639197
http://dx.doi.org/10.1007/s00415-022-11166-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9363350/
https://www.ncbi.nlm.nih.gov/pubmed/35639197
http://dx.doi.org/10.1007/s00415-022-11166-z

Ejemplares similares